Project Grant R42DK145320
Award Date 9/12/25
Completion Date 6/30/28
Dollars Obligated $280K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC, USA
Similar Awards
- This $109,076 Project Grant was awarded on July 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at Weill Medical College of Cornell University to investigate the structural basis and pharmacological inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which plays a key role in the development and...
- This $812,621 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to decipher the role of the cystic fibrosis transmembrane receptor (CFTR) in dietary fatty acid transport within the small intestine. The Principal Investigator is Alison B. Kohan, with Co-Principal Investigator CA Hodges. The project aims to use novel surgical...
- This Project Grant award of $613,558 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports Genetobe Inc., a Michigan-based biotechnology company, in developing novel, selective sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor compounds as an adjunctive therapy for cystic fibrosis (CF) associated metabolic disorders, including CF-associated liver disease and CF-related diabetes. The...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- The federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand the mechanisms linking the cystic fibrosis transmembrane conductance regulator (CFTR) gene to dysregulated barrier function, insulin receptor function, and glucose transport in the lungs of cystic fibrosis (CF) patients. The $730,494 award to Emory University, with a sub-award to Vanderbilt University Medical Center, aims to investigate...
- This $291,949 Project Grant was awarded on September 15, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant was awarded to Biosettia Inc. (UEI: GZM5S2UYEGD2) located in San Diego, CA to support research aimed at using deep sequencing to measure variants of the endogenous retrovirus (ERV) GAG gene as potential biomarkers for type 1 diabetes. The project seeks...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- This $859,704 Project Grant was awarded on July 2, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research by Weill Medical College of Cornell University to investigate the role of the protein AGR2 in regulating host-microbe interactions and inflammatory processes in Crohn's disease. The research aims to enhance understanding of the cellular...
- This $2,782,476 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) supports research to determine the molecular mechanisms underlying pancreatic beta cell response to metabolic stress, a key factor in the development of type 2 diabetes. The 4-year project aims to leverage in vitro human beta cell models, single-cell transcriptomic analyses, and targeted drug screening to delineate the dynamic chromatin and transcriptomic changes that...